Merck & Co., Inc. (NYSE:MRK) Declares $0.85 Quarterly Dividend

Merck & Co., Inc. (NYSE:MRK) announced a quarterly dividend on Wednesday, July 29th. Stockholders of record on Tuesday, September 15th will be paid a dividend of 0.85 per share on Wednesday, October 7th. This represents a c) dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date of this dividend is Tuesday, September 15th.

Merck & Co., Inc. has increased its dividend by an average of 0.1%per year over the last three years and has raised its dividend annually for the last 14 consecutive years. Merck & Co., Inc. has a dividend payout ratio of 35.0% meaning its dividend is sufficiently covered by earnings. Research analysts expect Merck & Co., Inc. to earn $9.72 per share next year, which means the company should continue to be able to cover its $3.40 annual dividend with an expected future payout ratio of 35.0%.

Merck & Co., Inc. Stock Performance

Merck & Co., Inc. stock opened at $130.45 on Thursday. The stock has a fifty day moving average price of $122.73 and a 200 day moving average price of $118.24. Merck & Co., Inc. has a 52 week low of $77.53 and a 52 week high of $135.05. The firm has a market capitalization of $322.18 billion, a P/E ratio of 36.75, a PEG ratio of 5.23 and a beta of 0.19. The company has a current ratio of 1.30, a quick ratio of 1.06 and a debt-to-equity ratio of 1.02.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.19. The firm had revenue of $16.29 billion for the quarter, compared to analyst estimates of $15.85 billion. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The firm’s quarterly revenue was up 4.9% on a year-over-year basis. During the same period last year, the company earned $2.22 EPS. Equities research analysts anticipate that Merck & Co., Inc. will post 2.74 earnings per share for the current year.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Barclays raises price target: Barclays increased its target for MRK from $140 to $150 and maintained an “overweight” rating, implying approximately 15% upside from the referenced share price. Barclays raises Merck price target
• Positive Sentiment: Higher long-term earnings forecast: Erste Group Bank raised its FY2027 earnings estimate for Merck to $9.54 per share from $9.52, a modestly favorable revision that suggests some confidence in the company’s longer-term outlook.
• Positive Sentiment: Ebola vaccine manufacturing initiative: Hilleman Laboratories, the Merck-Wellcome joint venture, is preparing to manufacture doses of an experimental vaccine targeting the Bundibugyo strain of Ebola for clinical trials. The effort could strengthen Merck’s public-health profile and create longer-term commercial opportunities, although it is not an immediate earnings driver. Merck and Wellcome Ebola vaccine partnership
• Neutral Sentiment: Dividend reaffirmed: Merck declared a quarterly dividend of $0.85 per share, payable October 7 to investors of record September 15. The annualized yield is approximately 2.6%, supporting the stock’s income appeal but offering little new information because the payment was expected. Merck announces fourth-quarter dividend
• Negative Sentiment: Upcoming earnings remain a concern: Analysts expect Merck’s second-quarter earnings to decline, and recent previews suggest the company lacks the factors typically associated with a likely earnings beat. This may be weighing on sentiment ahead of the report, despite the favorable longer-term estimate revision. Merck earnings preview

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.